Page 52 - Characterization of genetic neurodevelopmental disorders at adult age, with a focus on 22q11.2 deletion syndrome - Emma Boersma

Chapter 2
References
1. Hickman RA, O’Shea SA, Mehler MF, Chung WK. Neurogenetic disorders across the lifespan:
from aberrant development to degeneration. Nat Rev Neurol. Feb 2022;18(2):117-124.
doi:10.1038/s41582-021-00595-5
2. Saudubray JM, Garcia-Cazorla A. An overview of inborn errors of metabolism affecting the
brain: from neurodevelopment to neurodegenerative disorders. Dialogues Clin Neurosci. Dec
2018;20(4):301-325. doi:10.31887/DCNS.2018.20.4/jmsaudubray
3. Morato Torres CA, Wassouf Z, Zafar F, Sastre D, Outeiro TF, Schüle B. The Role of Alpha-
Synuclein and Other Parkinson’s Genes in Neurodevelopmental and Neurodegenerative
Disorders. International journal of molecular sciences. 2020;21(16):5724. doi:10.3390/
ijms21165724
4. Puschmann A. New Genes Causing Hereditary Parkinson’s Disease or Parkinsonism. Curr
Neurol Neurosci Rep. Sep 2017;17(9):66. doi:10.1007/s11910-017-0780-8
5. Morales-Briceno H, Mohammad SS, Post B, et al. Clinical and neuroimaging phenotypes of
genetic parkinsonism from infancy to adolescence. Brain. Dec 4 2019;doi:10.1093/brain/
awz345
6. Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
Parkinsonism Relat Disord. Oct 2019;67:74-89. doi:10.1016/j.parkreldis.2019.06.025
7. Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic
insights from Down syndrome. Nat Rev Neurosci. Sep 2015;16(9):564-74. doi:10.1038/nrn3983
8. Finucane BM, Myers SM, Martin CL, Ledbetter DH. Long overdue: including adults with brain
disorders in precision health initiatives. Curr Opin Genet Dev. Dec 2020;65:47-52. doi:10.1016/j.
gde.2020.05.001
9. Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of
Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet. Jun 27
2020;395(10242):1988-1997. doi:10.1016/s0140-6736(20)30689-9
10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Syst Rev. Jan 1 2015;4:1. doi:10.1186/2046-
4053-4-1
11. Köhler S, Carmody L, Vasilevsky N, et al. Expansion of the Human Phenotype Ontology
(HPO) knowledge base and resources. Nucleic Acids Res. Jan 8 2019;47(D1):D1018-d1027.
doi:10.1093/nar/gky1105
12. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease.
Mov Disord. Oct 2015;30(12):1591-601. doi:10.1002/mds.26424
13. Study Quality Assessment Tools. National Institutes of Health. Accessed April, 2020. https://
www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
14. Zschocke J. HSD10 disease: clinical consequences of mutations in the HSD17B10 gene. J
Inherit Metab Dis. Jan 2012;35(1):81-9. doi:10.1007/s10545-011-9415-4
15. Lake NJ, Bird MJ, Isohanni P, Paetau A. Leigh syndrome: neuropathology and pathogenesis. J
Neuropathol Exp Neurol. Jun 2015;74(6):482-92. doi:10.1097/nen.0000000000000195
16. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective
mitochondrial DNA polymerase. Nature. May 27 2004;429(6990):417-23. doi:10.1038/
nature02517
17. Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nat
Rev Neurol. Jan 2019;15(1):40-52. doi:10.1038/s41582-018-0101-0
18. Burke EA, Frucht SJ, Thompson K, et al. Biallelic mutations in mitochondrial tryptophanyl-
tRNA synthetase cause Levodopa-responsive infantile-onset Parkinsonism. Clin Genet. Mar
2018;93(3):712-718. doi:10.1111/cge.13172
19. Maynard TM, Meechan DW, Dudevoir ML, et al. Mitochondrial localization and function of a
subset of 22q11 deletion syndrome candidate genes. Mol Cell Neurosci. Nov 2008;39(3):439-
51. doi:10.1016/j.mcn.2008.07.027
50